Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Over 40,000 people picked up their packs to take part in the annual marathon in the capital.
The country's voters are concerned about security, the economy, and the 10% unemployment rate.
A pregnant woman and a man suffered "severe discomfort" after someone threw bleach at them from a passing car, hitting them in the eyes.